01.26.2021 - By NEJM Group
Inhibitors of sodium–glucose cotransporter 2 (SGLT2) are known to improve cardiovascular and renal outcomes in patients with type 2 diabetes. Until recently, less was known about the effects of SGLT2 inhibitors on heart failure. In this episode of Curbside Consults, we...